论文部分内容阅读
目的 观察腹膜透析 (PD)及血液透析 (HD)在糖尿病肾病肾脏替代治疗中的利弊。方法 选取我院糖尿病肾病患者 ,其中行血液透析 2 4例 ,腹膜透析 38例 ;两组患者的性别、透析前的年龄及残余肾功能均相匹配 ;比较两组的生存率及血脂、血糖、白蛋白、血红蛋白等指标。结果 两组前 2年的生存率差异无显著性 ;腹膜透析组第 3年的生存率大幅下降 ,明显低于血液透析组 (P <0 0 1) ;PD组的空腹血糖、甘油三酯及低密度脂蛋白均高于HD组 ,差异有显著性。PD组的血浆白蛋白水平显著低于HD组 (P <0 0 5 ) ,而血红蛋白则高于HD组。结论 对于糖尿病肾病的肾脏替代治疗 ,腹膜透析相对于血液透析仍存在一些不完善的地方 ;是否以腹膜透析作为糖尿病肾病终末期的首选治疗方案 ,尚需大量的、严格的临床对照研究
Objective To observe the advantages and disadvantages of peritoneal dialysis (PD) and hemodialysis (HD) in renal replacement therapy of diabetic nephropathy. Methods The patients with diabetic nephropathy were selected from our hospital, including 24 hemodialysis patients and 38 peritoneal dialysis patients. The gender, pre-dialysis age and residual renal function were matched. The survival rate, blood lipid, blood glucose, Albumin, hemoglobin and other indicators. Results There was no significant difference in survival rate between the two groups in the first two years. The survival rate of the peritoneal dialysis group in the third year was significantly lower than that in the hemodialysis group (P <0.01). The fasting blood glucose, triglyceride, Low density lipoprotein were higher than HD group, the difference was significant. Plasma albumin levels in PD group were significantly lower than those in HD group (P <0.05), while hemoglobin was higher in HD group than in HD group. Conclusion There are still some imperfections in peritoneal dialysis compared with hemodialysis for diabetic renal replacement therapy. Whether peritoneal dialysis is the first choice of the final stage of diabetic nephropathy requires a large number of rigorous clinical controlled studies